Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported extended interim results in first-line pancreatic cancer (PDAC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in the phase I/IIa CANFOUR trial. The efficacy was superior to historical data for chemotherapy only. In the 73 patients evaluable, median overall survival (OS) was 12.7 months with 1-year survival of 57% and median progression-free survival (iPFS) of 7.2 months. The safety profile was acceptable and in line with the earlier data set. These data strengthen previous positive